

1	2	3	4
24.	Tulip Hospital	Pvt.	M11. Dermatology, M16. General Medicine, M3. Critical Care, M5. Infectious Diseases, S1. General Surgery, S10. Neurosurgery, S11. Surgical Oncology, S12. Plastic Surgery, S14. Poly Trauma, S15. Prostheses, S2. ENT Surgery, S4. Gynaecology and Obstetrics Surgery, S5. Orthopedic Surgery and Procedures, S9. Genitourinary System
25.	Warana Institute	Pvt.	S9. Genitourinary System
26.	Kolhapur Cancer Center	Pvt.	M1. Medical Oncology, M2. Radiation Oncology, S11. Surgical Oncology
27.	Siddhagiri Hospital and Research Centre	Pvt.	M1. Medical Oncology, M10. Pulmonology, M14. Gastroenterology, M16. General Medicine, M3. Critical Care, M5. Infectious Diseases, M7. Cardiology, M9. Neurology, S1. General Surgery, S10. Neurosurgery, S11. Surgical Oncology, S14. Poly Trauma, S15. Prostheses, S4. Gynaecology and Obstetrics Surgery, S5. Orthopedic Surgery and Procedures, S9. Genitourinary System
28.	Ramkrishna Jaiswal Hospital	Pvt.	M10. Pulmonology, M14. Gastroenterology, M16. General Medicine, M3. Critical Care, M5. Infectious Diseases, M6. Pediatrics Medical Management, M9. Neurology, S1. General Surgery, S10. Neurosurgery, S12. Plastic Surgery, S13. Burns, S14. Poly Trauma, S15. Prostheses, S2. ENT Surgery, S4. Gynaecology and Obstetrics Surgery, S5. Orthopedic Surgery and Procedures, S6. Surgical Gastro Enterology, S8. Pediatric Surgery, S9. Genitourinary System

National Policy for Treatment of Rare Diseases

2163. SHRI SUSHIL KUMAR GUPTA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that several children suffering from rare diseases have succumbed to death while the Ministry is struggling with scarcity of funds for implementing the National Policy for Treatment of Rare Diseases;

(b) whether the Ministry has sent any request to the Ministry of Finance for providing funds for implementation of this Policy under the Rashtriya Arogya Nidhi;

(c) if so, the response of the Finance Ministry thereto;

(d) whether Government has set up any technical Committees and rare diseases cells for treatment of patients under this policy; and

(e) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI ASHWINI KUMAR CHOUBEY): (a) Public Health and Hospitals is a State subject and it is the primary responsibility of the State Governments to address the healthcare needs of its population. No such information has been received from State Governments.

(b) and (c) The Standing Finance Committee of the Ministry of Health and Family Welfare, comprising of Ministry of Finance, has approved a proposal for adding a sub-component under the Umbrella Scheme of Rashtriya Arogya Nidhi (RAN) for provision of financial assistance for specified rare diseases which require one-time treatment.

(d) and (e) The Central Government had set up a Rare Diseases Cell and a Central Technical Committee (CTC) as per the provisions of the erstwhile National Policy for Treatment of Rare Diseases 2017. Some State Governments namely, Delhi, Karnataka, Punjab, Gujarat, Jharkhand and Tamil Nadu had also reported to have constituted State Technical Committees.

Funds for public immunisation programme

2164. SHRI DEREK O'BRIEN: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether the Ministry is concerned that injectible Inactivated Poliovirus Vaccine (IPV) will soon become more expensive and if so, the reasons therefor;

(b) whether Government has approached international donors for financial help to support its public immunisation programme, including immunisation of infants using IPV;

(c) if so, the amount of funds required over and above the budget allocated by Government to fund the public immunisation programme; and

(d) whether there is a need to increase Government investment in healthcare and the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI ASHWINI KUMAR CHOUBEY): (a) Yes. Ministry is aware of the price rise for injectable Inactivated Polio Virus Vaccine (IPV). The recent price is 80% higher than the Last Procurement Price (LPP).